We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
12.50 | 0.76% | 1,653.00 | 1,654.00 | 1,655.00 | 1,655.50 | 1,634.00 | 1,638.50 | 3,990,601 | 16:35:15 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.83 | 68.14B |
Date | Subject | Author | Discuss |
---|---|---|---|
18/1/2023 15:05 | Thanks Michael . When do you see a step change upwards in the share price ? | alibizzle | |
18/1/2023 14:36 | Earnings per Share (EPS) is calculated as a company's profit divided by the outstanding shares of its common stock. The resulting number serves as an indicator of a company's profitability. | tradermichael | |
18/1/2023 13:29 | Ah ok , what's EPS? | alibizzle | |
18/1/2023 12:47 | Possible doubts about Q4 earnings. Can this be matched: '21 Q4 EPS beaten by 9% '22 Q1 EPS beaten by 174% '22 Q2 EPS beaten by 16% '22 Q3 EPS beaten by 20% '22 Q4 results due 01 Feb ? | tradermichael | |
18/1/2023 12:08 | Sizeable fall today , possible due to bad forecast from banks about GSK projected sp | alibizzle | |
18/1/2023 09:45 | Morgan Stanley really needs to find something else to say was that worth it?And they never say a reason!!! | mj19 | |
18/1/2023 08:13 | 16 Jan 2023 07:41amGSK : MORGAN STANLEY CUTS TARGET PRICE TO 1520P FROM 1535PThis news story contains no content | mj19 | |
18/1/2023 08:10 | Heading back to the 1300s | spoole5 | |
14/1/2023 10:15 | Do you think after we hopefully have some good news in Florida next month with litigation that share price will start really picking up , or is there another event which may precipitate a step change ( other than a take over ) | alibizzle | |
13/1/2023 13:41 | Good expression . All the analysts such as JP Morgan say at best £15 in 2023 . | alibizzle | |
12/1/2023 15:09 | Rich man's yo yo? | rikky72 | |
12/1/2023 14:54 | What is share doing directionless up in morning and back down in afternoon | mj19 | |
12/1/2023 09:51 | Yes, dividend reached my AJ Bell accounts this morning .... ;0) | tradermichael | |
12/1/2023 09:18 | Divi day today,shares are cheap too. | abdullla | |
11/1/2023 21:30 | This is quite a big move by the US FDA. New medicines need not be tested in animals to receive U.S. Food and Drug Administration (FDA) approval, according to legislation signed by President Joe Biden in late December 2022. The change—long sought by animal welfare organizations— safety regulation. In place of the 1938 stipulation that potential drugs be tested for safety and efficacy in animals, the law allows FDA to promote a drug or biologic—a larger molecule such as an antibody—to human trials after either animal or non-animal tests. It is a very complex area and for example, animal tissue could be used in tox studies - it is just that the animal is dead. | alphorn | |
11/1/2023 12:33 | It's not doing much at the moment. I topped up its at reasonable price. Bought some at £15.20 and now again.. | mj19 | |
11/1/2023 10:15 | Some may be interested. ”GSK plc (GSK) Presents at 41st Annual JPMorgan Healthcare Conference” There is an option to listen to the pitch as well (Press Play Earnings Call button) | geckotheglorious | |
11/1/2023 08:05 | Well, I kept within the Normal Market Size! Good luck. | tradermichael | |
10/1/2023 21:05 | Me too funnily enough, although I suspect you bought a few more than I did ;) | rikky72 | |
10/1/2023 12:47 | IN @ 1415.00 ..... ;0) | tradermichael | |
10/1/2023 12:17 | I hope not diku but wouldn't be surprised to see 13 something soon. | tuftymatt | |
10/1/2023 12:04 | Is this heading back down to 1300 - 1320p?... | diku |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions